Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Titel:
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
Auteur:
Rimner, Andreas Lai, Wei-Chu Victoria Califano, Raffaele Jabbour, Salma K. Rudin, Charles M. Faivre-Finn, Corinne Cho, Byoung Chul Kato, Terufumi Yu, Jinming Chafin, Wyatt Yu, Li Zhao, Bin Byers, Lauren